Jiangsu Cancer Institute & Hospital
Clinical trials sponsored by Jiangsu Cancer Institute & Hospital, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill combo offers hope for Hard-to-Treat esophageal cancer Results expected Dec 2026 (estimated)
- New study aims to unlock clues in nasopharyngeal cancer Results expected Jun 2027 (estimated)
-
New cocktail of drugs hopes to tackle tough breast cancer
Disease control Recruiting nowThis phase II trial is testing a combination of three drugs—QL1706 (an immunotherapy), anlotinib (a targeted therapy), and nab-paclitaxel (chemotherapy)—as a first treatment for advanced triple-negative breast cancer. The study will enroll 34 women and aims to see if the combo ca…
Phase 2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New pill combo offers hope for Hard-to-Treat esophageal cancer
Disease control Recruiting nowThis study is testing whether a chemotherapy pill (oral paclitaxel) combined with radiation can safely treat advanced esophageal cancer that cannot be removed by surgery. It is for people aged 70 or older, or those who cannot tolerate standard IV chemo. The goal is to control the…
Phase 2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New Immune-Chemo cocktail aims to shrink inoperable lung tumors
Disease control Recruiting nowThis phase 2 trial is testing a combination of two immune-boosting antibodies (iparomlimab and tuvonralimab) plus chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. The study will enroll 33 adults who have not had prior treatment.…
Phase 2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug cocktail targets hard-to-treat ovarian cancer in early trial
Disease control Recruiting nowThis phase 2 study is testing a combination of three drugs (disitamab vedotin, carboplatin, and bevacizumab) as first treatment and ongoing therapy for women with a specific type of advanced ovarian cancer that has a protein called HER2 and lacks a repair deficiency (HRD-negative…
Phase 2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC